Similarly, using prostate cancer as a model, Juanjuan Li and colleagues showed that interventions targeting the CAF-associated CXCL12–CXCR4 pathway can remodel both the stromal and immune microenvironment. This evidence concerns the gene CXCR4 and prostate carcinoma.